Graphic: corner
spacer
Graphic: corner
spacer spacer
nav left edge
nav right edge
spacer

Joint Statement by OptiGen and InGen - December 4, 2012

OptiGen, LLC and International Genetics, Inc., Genetic Fulfillment USA, LLC, PinPoint DNA Technologies, Inc., and Richard B. Dobbins (the ďInGen DefendantsĒ) have resolved OptiGenís patent infringement, unfair competition, and Lanham Act claims against the InGen defendants related to their testing of canine DNA for certain genetic disorders.  Mr. Dobbins is the CEO of PinPoint DNA Technologies, Inc. and the founder, CEO, and General Manager of International Genetics, Inc. (also known as InGen). 

In January and April 2009, OptiGen filed lawsuits arising out of the infringement of a number of patents to which OptiGen holds exclusive licenses.  The consolidated actions charged the InGen defendants, among others, with infringement of patents related to the testing of PRCD (Progressive Rod-Cone Degeneration), CLAD (Canine Leukocyte Adhesion Deficiency), CSNB/prad (Congenital Stationary Night Blindness or Retinal Dystrophy), and FN (Autosomal Recessive Nephropathy).  The testing of these genetic disorders is covered by the following patents to which OptiGen holds exclusive licenses:  U.S. Patent Nos. 5,804,388; 7,312,037; 7,285,388; 6,210,897; 6,201,114; and 6,428,958.  The InGen defendants offered to sell and sold DNA testing products that utilized the methods covered by OptiGenís patents to customers located in the United States.

The InGen defendants have agreed to settle OptiGenís claims.  Under the settlement, the InGen defendants have, among other things, ceased any and all sales of testing related to these patents and have agreed not to resume any such testing in the future.  The InGen defendants regret that their testing has caused confusion among the community of dog owners and breeders.


For further details please see the Court's Consent Judgement


spacer
Graphic: footer bar left
OptiGen®, LLC · Cornell Business & Technology Park · 767 Warren Road, Suite 300 · Ithaca, New York 14850
Tel: 607 257 0301 · Fax: 607 257 0353 · email: genetest@optigen.com or optigen@clarityconnect.com
Graphic: footer bar right
spacer spacer
spacer
spacer
spacer